The Nanobodies market is estimated to be valued at US$ 368.6 Million In 2022 and is expected to exhibit a CAGR of 24.1% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview: Nanobodies are single domain antigen binding fragments derived from camelids, which include camels, llamas and alpacas. Nanobodies exhibit high affinity, specificity, thermostability. Due to their small size, nanobodies can bind epitopes that are difficult for regular antibody fragments to access. The unique properties of nanobodies make them suitable for various applications in research, diagnostics and therapeutics. Market Dynamics: The nanobodies market is driven by increasing demand from the healthcare industry for diagnosis and treatment of various diseases. Nanobodies can be used as an alternative to monoclonal antibodies in immunotherapy due to advantages such as small size, low cost production through microbial system. Advancements in recombinant DNA technologies have enabled large-scale production of nanobodies, thus fueling market growth. Nanobodies exhibit high stability at elevated temperatures, allowing their use in developing robust diagnostic tests. Their small size allows deeper tissue penetration compared to regular antibodies. SWOT Analysis Strength: The Nanobodies Market has strong growth potential due to their small molecular size, high stability, specificity, and ease of production. Nanobodies are cheaper to produce and more potent than monoclonal antibodies. Their small size allows them to access disease targets that are difficult or impossible for regular antibodies to reach. Weakness: The market is currently at a nascent stage with limited availability of nanobodies and high production costs. The clinical validation and drug development process also takes significant time and resources. Lack of expertise and awareness can hamper market growth. Opportunity: Increasing R&D investments by biotech companies and growing nanomedicine applications present lucrative opportunities. Rising demand for targeted disease therapies and protein engineering also drives the nanobodies market. Growing prevalence of cancer, infectious diseases, and autoimmune disorders expands the customer base. Threats: Stringent regulatory frameworks and lengthy approval procedures pose threats. Complex production technology and dependence on contract manufacturers for large-scale synthesis challenges cost effectiveness. Intense competition from alternative drug formulations can impede market penetration. Key Takeaways The global nanobodies market is expected to witness high growth, exhibiting a CAGR of 24.1% over the forecast period, due to increasing R&D investment in biologics and technological advancements in protein engineering. Regional analysis: North America currently dominates the nanobodies market, accounting for over 35% revenue share in 2023 owing to strong government support and presence of key industry players. Asia Pacific is anticipated to be the fastest growing region due to rising healthcare expenditure, growing biologics industry, and increasing outsourcing of clinical trials to China and India. Key players: Key players operating in the nanobodies market are Merck KGaA, Sanofi, AlpalifeB Inc, GenScript, Novartis International AG, Taisho Pharmaceutical Holdings Co., Ltd., Sino Biological, Inc., GeneMedi, Biocytogen, Abnova Corporation, NanoTag Biotechnologies, Avillion LLP, Capra Science, Numab Therapeutics, CUSABIO TECHNOLOGY LLC, Proteintech Group, Inc., GT Biopharma, Inc., Confo Therapeutics, R&D Systems, Inc., Abcepta Biotech Ltd. Co. These players are focused on R&D investments to develop innovative nanobody therapeutics. Read More : https://www.ukwebwire.com/the-emerging-nanobodies-market-forecast-analysis-demand/
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
September 2023
Categories |